PET-CT in Lung Cancer

  • Roxani D. EfthymiadouEmail author


Today, lung cancer is the most common cause of death from cancer in both men and women in the developed countries. An appropriate staging is of great value for patient’s management and prognosis. PET-CT is widely used in lung cancer because of its superiority, compared to other imaging modalities, in the detection of nodal and metastatic disease. PET-CT combines in one single method the detailed anatomic information provided by CT with the functional data provided by PET. 18F-FDG PET-CT currently is indicated for the characterization of lung lesions, staging of non-small cell lung carcinoma (NSCLC), detection of distant metastases, diagnosis of recurrent disease, planning radiotherapy, and treatment monitoring. PET-CT has proved to be a cost-effective method in the evaluation of lung cancer. In about 35% of cases first staged with CT, the stage of the disease has changed—in most cases the disease is upstaged—after subsequent PET-CT, with resultant changes in patient’s management. PET-CT is also a useful and promising method for the evaluation of SCLC—in selected cases—but its role remains under study.


PET-CT NSCLC SCLC Lung cancer Staging Radiotherapy planning 


  1. 1.
    Bunyaviroch T, Coleman R (2006) PET evaluation of lung cancer. J Nucl Med 47(3):451–469PubMedGoogle Scholar
  2. 2.
    Fanti S, Franchi R, Batista G et al (2005) PET and PET-CT. State of the art and future prospects. Radiol Med 110:1–15PubMedGoogle Scholar
  3. 3.
    Ambrosini V, Nicolini S, Caroli P et al (2012) PET/CT imaging in different types of lung cancer: an overview. Eur J Radiol 81(5):988–1001CrossRefGoogle Scholar
  4. 4.
    Vahid R, Dabbagh K (2007) Positron emission tomography (PET) in the management of lung cancer. Rev Pneumon 20(1):43–48Google Scholar
  5. 5.
    UyBico SJ’, Wu C, Suh R et al (2010) Lung cancer staging essentials: the new TNM staging system and potential imaging pitfalls. Radiographics 30:1163–1181CrossRefGoogle Scholar
  6. 6.
    Kligerman S, Digumarthy S (2009) Staging of non–small cell lung cancer using integrated PET/CT. AJR 193(5):1203–1211CrossRefGoogle Scholar
  7. 7.
    Czernin J, Schelbert H (2004) PET/CT imaging: facts, opinions, hopes, and questions. J Nucl Med 45((Supp l)):1SGoogle Scholar
  8. 8.
    Bradley J, Thorstad WL, Mutic S et al (2007) Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 59:4–5Google Scholar
  9. 9.
    Hanin FX, Lonneux M, Cornet J et al (2008) Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur J Cardiothorac Surg 33:819–823CrossRefGoogle Scholar
  10. 10.
    Saif MW, Tzannou I, Makrilia N et al (2010) Role and cost effectiveness of PET/CT in management of patients with cancer. Yale J Biol Med 83:53–65PubMedPubMedCentralGoogle Scholar
  11. 11.
    Fischer BM, Mortensen J, Langer SW et al (2006) PET/CT imaging in response evaluation of patients with small cell lung cancer. Lung Cancer 54:41–49CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.CT, MRI and PET-CT DepartmentHygeia HospitalAttikiGreece

Personalised recommendations